383 related articles for article (PubMed ID: 28526474)
1. Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance.
Patel H; Pawara R; Ansari A; Surana S
Eur J Med Chem; 2017 Dec; 142():32-47. PubMed ID: 28526474
[TBL] [Abstract][Full Text] [Related]
2. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
Tan CS; Cho BC; Soo RA
Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
[TBL] [Abstract][Full Text] [Related]
3. EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance.
Wang S; Song Y; Liu D
Cancer Lett; 2017 Jan; 385():51-54. PubMed ID: 27840244
[TBL] [Abstract][Full Text] [Related]
4. In-silico evidences for binding of Glucokinase activators to EGFR C797S to overcome EGFR resistance obstacle with mutant-selective allosteric inhibition.
Patel H; Pawara R; Surana S
Comput Biol Chem; 2018 Jun; 74():167-189. PubMed ID: 29627693
[TBL] [Abstract][Full Text] [Related]
5. Crystal structure of EGFR T790M/C797S/V948R in complex with EAI045.
Zhao P; Yao MY; Zhu SJ; Chen JY; Yun CH
Biochem Biophys Res Commun; 2018 Jul; 502(3):332-337. PubMed ID: 29802850
[TBL] [Abstract][Full Text] [Related]
6. Targeting EGFR
Lu X; Yu L; Zhang Z; Ren X; Smaill JB; Ding K
Med Res Rev; 2018 Sep; 38(5):1550-1581. PubMed ID: 29377179
[TBL] [Abstract][Full Text] [Related]
7. Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?
Sun JM; Park K
Curr Opin Oncol; 2017 Mar; 29(2):89-96. PubMed ID: 28085680
[TBL] [Abstract][Full Text] [Related]
8. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
Ou SH; Soo RA
Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
[TBL] [Abstract][Full Text] [Related]
9. The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.
Niederst MJ; Hu H; Mulvey HE; Lockerman EL; Garcia AR; Piotrowska Z; Sequist LV; Engelman JA
Clin Cancer Res; 2015 Sep; 21(17):3924-33. PubMed ID: 25964297
[TBL] [Abstract][Full Text] [Related]
10. Rational Computational Design of Fourth-Generation EGFR Inhibitors to Combat Drug-Resistant Non-Small Cell Lung Cancer.
Park H; Jung HY; Kim K; Kim M; Hong S
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33297461
[TBL] [Abstract][Full Text] [Related]
11. Managing acquired resistance in EGFR-mutated non-small cell lung cancer.
Forde PM; Ettinger DS
Clin Adv Hematol Oncol; 2015 Aug; 13(8):528-32. PubMed ID: 26351816
[TBL] [Abstract][Full Text] [Related]
12. LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo.
Liu Y; Lai M; Li S; Wang Y; Feng F; Zhang T; Tong L; Zhang M; Chen H; Chen Y; Song P; Li Y; Bai G; Ning Y; Tang H; Fang Y; Chen Y; Lu X; Geng M; Ding K; Yu K; Xie H; Ding J
Cancer Sci; 2022 Feb; 113(2):709-720. PubMed ID: 34855271
[TBL] [Abstract][Full Text] [Related]
13. p38α MAP kinase inhibitors to overcome EGFR tertiary C797S point mutation associated with osimertinib in non-small cell lung cancer (NSCLC): emergence of fourth-generation EGFR inhibitor.
Ahmad I; Shaikh M; Surana S; Ghosh A; Patel H
J Biomol Struct Dyn; 2022 Apr; 40(7):3046-3059. PubMed ID: 33174519
[TBL] [Abstract][Full Text] [Related]
14. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
15. Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer.
Noda S; Kanda S
Expert Rev Respir Med; 2016; 10(5):547-56. PubMed ID: 26959310
[TBL] [Abstract][Full Text] [Related]
16. Rociletinib, a third generation EGFR tyrosine kinase inhibitor: current data and future directions.
Chuang JC; Salahudeen AA; Wakelee HA
Expert Opin Pharmacother; 2016; 17(7):989-93. PubMed ID: 26950414
[TBL] [Abstract][Full Text] [Related]
17. Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer.
Chen L; Fu W; Zheng L; Liu Z; Liang G
J Med Chem; 2018 May; 61(10):4290-4300. PubMed ID: 29136465
[TBL] [Abstract][Full Text] [Related]
18. Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer.
Song HN; Jung KS; Yoo KH; Cho J; Lee JY; Lim SH; Kim HS; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Park W; Ahn MJ
J Thorac Oncol; 2016 Apr; 11(4):e45-7. PubMed ID: 26749488
[TBL] [Abstract][Full Text] [Related]
19. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies.
Lim SM; Syn NL; Cho BC; Soo RA
Cancer Treat Rev; 2018 Apr; 65():1-10. PubMed ID: 29477930
[TBL] [Abstract][Full Text] [Related]
20. [Mechanism and clinical efficacy of third-generation epidermal growth factor receptor tyrosine kinase inhibitor in non-small cell lung cancer].
Chen XX; Zhou CC
Zhonghua Zhong Liu Za Zhi; 2017 Jun; 39(6):401-404. PubMed ID: 28635227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
